Tissue factor and fibrin in tumor angiogenesis

Seminars in Thrombosis and Hemostasis

Volumn 30, Issue 1, 2004, Pages 31-44

  Fernandez, Patricia M ^b,c   Patierno, Steven R ^b,c   Rickles, Frederick R ^a,b  

^a Federation of American Societies for Experimental Biology   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Angiogenesis; Clot; Fibrin; Low molecular weight heparin; Tissue factor

Indexed keywords

ANGIOPOIETIN 1; ANTICOAGULANT AGENT; ENDOSTATIN; FIBRIN; FIBROBLAST GROWTH FACTOR 2; HEPARIN; INTERFERON; INTERLEUKIN 8; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE; SEMAXANIB; THROMBIN; THROMBOCYTE FACTOR; THROMBOPLASTIN; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOOD CLOTTING; CANCER; CARCINOGENESIS; CELL PROLIFERATION; CYTOPLASM; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TARGETING; EMBRYO DEVELOPMENT; HUMAN; HYPERCOAGULABILITY; METASTASIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THROMBOEMBOLISM; TUMOR GROWTH;

ANIMALS; FIBRIN; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOPHILIA; THROMBOPLASTIN;

EID: 0344460027     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-822969     Document Type: Review

References (154)

1. Trousseau A. Phlegmasia alba dolens. In: Clinique Médicale de l'Hôtel-Dieu de Paris. Paris: JB Balliere et Fils; 1865;3:654-712
2. Rickles FR, Levine MN, Dvorak HF. Abnormalities of hemostasis in malignancy. In: Colman RW, Hirsh J, Marder VJ, Clower AW, George JN, eds. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott Williams & Wilkins; 2001:1131-1152
3. Hillen HF. Thrombosis in cancer patients. Ann Oncol 2000;11:273-276
4. Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: the role of a bifunctional coagulation cofactor. Thomb Res 1985;40:351-358
5. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993;81:734-744
6. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001;86:66-74
7. Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost 2001;86:959-972
8. Carmeliet P, Mackman N, Moons L, et al. Role of tissue factor in embryonic blood vessel development. Nature 1996;383:73-75
9. Bugge TH, Xiao Q, Kombrinck KW. Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of coagulation. Proc Natl Acad Sci USA 1996;93:6258-6263
10. Toomey JR, Kratzer KE, Lasky NM, Stanton JJ, Broze GJ Jr. Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 1996;88:1583-1587
11. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439
12. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442
13. Peppelenbosch MP, Versteeg HH. Cell biology of tissue factor, an unusual member of the cytokine receptor family. Trends Cardiovasc Med 2001;11:335-339
14. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996;2:209-215
15. Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer 2000;83:164-170
16. Hair GA, Padula S, Zeff R, et al. Tissue factor expression in human leukemic cells. Leuk Res 1996;20:1-11
17. Guan M, Jin J, Su B, Liu WW, Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002;35:321-325
18. Guan M, Su B, Lu Y. Quantitative reverse transcription-PCR measurement of tissue factor mRNA in glioma. Mol Biotechnol 2002;20:123-129
19. Koomagi R, Volm M. Tissue factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis. Int J Cancer 1998;79:19-22
20. Sawada M, Miyake S, Ohdama S, et al. Expression of tissue factor in non-small-cell lung cancers and its relationship to metastasis. Br J Cancer 1999;79:472-477
21. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000;88:295-301
22. Shigemori C, Wada H, Matsumoto K, Shiku H, Nakamura S, Suzuki H. Tissue factor expression and metastatic potential of colorectal cancer. Thromb Haemost 1998;80:894-898
23. Nakasaki T, Wada H, Shigemori C, et al. Expression of tissue factor and vascular endothelial growth factor is associated with angiogenesis in colorectal cancer. Am J Hematol 2002;69:247-254
24. Ueda C, Hirohata Y, Kihara Y, et al. Pancreatic cancer complicated by disseminated intravascular coagulation associated with production of tissue factor. J Gastroenterol 2001;36:848-850
25. Lwaleed BA, Cooper AJ. Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu. Med Hypotheses 2000;55:470-473
26. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999;96:8663-8668
27. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327
28. Shoji M, Hancock WW, Abe K, et al. Activation of coagulation and angiogenesis in cancer. Immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. Am J Pathol 1998;152:399-411
29. Mechtcheriakova D, Wlachos A, Holzmüller H, Binder BR, Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 1999;93:3811-3823
30. Blum S, Issbruker K, Willuweit A, et al. An inhibitory role of the phosphatidylinositol 3-kinase signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 2001;276:33428-33434
31. Kim I, Oh J-L, Ryu YS, et al. Angiopoietin-1 negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 2002;16:126-128
32. Bach R. Mechanism of tissue factor activation on cells. Blood Coagul Fibrinolysis 1998;9:S37-S43
33. Nemerson Y, Giesen PL. Some thoughts about localization and expression of tissue factor. Blood Coagul Fibrinolysis 1998;9:S45-S47
34. Rao LV, Pendurthi UR. Tissue factor on cells. Blood Coagul Fibrinolysis 1998;9:S27-S35
35. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor deencryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms. Blood Coagul Fibrinolysis 1999;10:201-210
36. Carson SD, Bromberg ME. Tissue factor encryption/deencryption is not altered in the absence of the cytoplasmic domain. Thromb Haemost 2000;84:657-663
37. Sevinsky JR, Rao LV, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. J Cell Biol 1996;133:293-304
38. Shin J-S, Abraham SN. Caveolae - not just craters in the cellular landscape. Science 2001;293:1447-1448
39. Carson SD. Manifestation of cryptic fibroblast tissue factor occurs at detergent concentrations which dissolve the plasma membrane. Blood Coagul Fibrinolysis 1996;7:303-313
40. Camera M, Giesen PLA, Fallon J, et al. Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:531-537
41. Rickles FR, Shoji M, Abe K. The role of the hemostatic system in tumor growth, metastasis, and angiogenesis: tissue factor is a bifunctional molecule capable of inducing both fibrin deposition and angiogenesis in cancer. Int J Hematol 2001;73:145-150
42. Fernandez PM, Rickles FR. Tissue factor and angiogenesis in cancer. Curr Opin Hematol 2002;9:401-406
43. Carmeliet P. Biomedicine. Clotting factors build blood vessels. Science 2001;93:1602-1604
44. Coughlin SR. Protease-activated receptors in vascular biology. Thromb Haemost 2001;86:298-307
45. Rottingen JA, Enden T, Camerer E, Iversen JG, Prydz H. Binding of human factor VIIa to tissue factor induces cytosolic Ca2+ signals in J82 cells, transfected COS-1 cells, Madin-Darby canine kidney cells and in human endothelial cells induced to synthesize tissue factor. J Biol Chem 1995;270:4650-4660
46. Poulsen LK, Jacobsen N, Sorensen BB, et al. Signal transduction via the mitogen-activated protein kinase pathway induced by binding of coagulation factor VIIa to tissue factor. J Biol Chem 1998;273:6228-6232
47. Camerer E, Rottingen JA, Gjernes E, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999;274:32225-32233
48. Sorensen BB, Freskgard PO, Nielsen LS, Rao LV, Ezban M, Petersen LC. Factor VIIa-induced p44/42 mitogen-activated protein kinase activation requires the proteolytic activity of factor VIIa and is independent of the tissue factor cytoplasmic domain. J Biol Chem 1999;274:21349-21354
49. Chen J, Bierhaus A, Schiekofer S, et al. Tissue factor - a receptor involved in the control of cellular properties, including angiogenesis. Thromb Haemost 2001;86:334-345
50. Ollivier V, Bentolila S, Chabbat J, Hakim J, de Prost D. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998;91:2698-2703
51. Ollivier V, Chabbat J, Herbert JM, Hakim J, de Prost D. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa. Arterioscler Thromb Vasc Biol 2000;20:1374-1381
52. Bromberg ME, Sundaram R, Homer RJ, Garen A, Königsberg WH. Role of tissue factor in metastasis: functions of the cytoplasmic and extracellular domains of the molecule. Thromb Haemost 1999;82:88-92
53. Tsopanoglou NE, Pipili-Synetos E, Maragoudakis ME. Thrombin promotes angiogenesis by a mechanism independent of fibrin formation. Am J Physiol 1993;264:C1302-C1307
54. Richard DE, Vouret-Craviari V, Pouyssegur J. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 2001;20:1556-1562
55. Tsopanoglou NE, Maragoudakis ME. On the mechanism of thrombin-induced angiogenesis. Potentiation of vascular endothelial growth factor activity on endothelial cells by up-regulation of its receptors. J Biol Chem 1999;274:23969-23976
56. Wojtukiewicz MZ, Sierko E, Klement P, Rak J. The hemostatic system and angiogenesis in malignancy. Neoplasia 2001;3:371-384
57. Nagy JA, Brown LF, Senger DR, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989;948:305-326
58. Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Ann N Y Acad Sci 2001;936:11-30
59. Medved L, Tsurupa G, Yakovlev S. Conformational changes upon conversion of fibrinogen into fibrin. The mechanisms of exposure of cryptic sites. Ann N Y Acad Sci 2001;936:185-204
60. Hantgan RP, Simpson-Haidaris PJ, Francis CW, Marder VJ. Fibrinogen structure and physiology. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice Philadelphia, PA: Lippincott Williams & Wilkins; 2001:203-232
61. Doolittle RF. Fibrinogen and fibrin. Sci Am 1981;245:126-135
62. Bootle-Wilbraham CA, Tazzyman S, Marshall JM, Lewis CE. Fibrinogen E-fragment inhibits the migration and tubule formation of human dermal microvascular endothelial cells in vitro. Cancer Res 2000;60:4719-4724
63. Degen JL, Drew AF, Palumbo JS, et al. Genetic manipulation of fibrinogen and fibrinolysis in mice. Ann N Y Acad Sci 2001;936:276-290
64. Virchow R. Gesammelte Abhandlungen zur wissenschaftliden Medizin. Frankfurt, Germany: Meidinger Sohn; 1856
65. Altieri DC, Mannucci PM, Capitanio AM. Binding of fibrinogen to human monocytes. J Clin Invest 1986;78:968-976
66. Felding-Habermann B, Ruggeri ZM, Cheresh DA. Distinct biological consequences of integrin alpha v beta 3-mediated melanoma cell adhesion to fibrinogen and its plasmic fragments. J Biol Chem 1992;267:5070-5077
67. Dejana E, Languino LR, Polentarutti N, et al. Interaction between fibrinogen and cultured endothelial cells. Induction of migration and specific binding. J Clin Invest 1985;75:11-18
68. Donaldson DJ, Mahan JT, Amrani DL, Farrell DH, Sobel JH. Further studies on the interaction of migrating keratinocytes with fibrinogen. Cell Adhes Commun 1994;2:299-308
69. Brown LF, Lanir N, McDonagh J, Tognazzi K, Dvorak AM, Dvorak HF. Fibroblast migration in fibrin gel matrices. Am J Pathol 1993;142:273-283
70. Naito M, Funaki C, Hayashi T, et al. Substrate-bound fibrinogen, fibrin and other cell attachment-promoting proteins as a scaffold for cultured vascular smooth muscle cells. Atherosclerosis 1992;96:227-234
71. Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann N Y Acad Sci 1983;408:28-43
72. Odrljin TM, Shainoff JR, Lawrence SO, Simpson-Haidaris PJ. Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain. Blood 1996;88:2050-2061
73. Odrljin TM, Francis CW, Sporn LA, Bunce LA, Marder VJ, Simpson-Haidaris PJ. Heparin binding domain of fibrin mediates its binding to endothelial cells. Arterioscler Thromb Vasc Biol 1996;16:1544-1551
74. Altieri DC, Duperray A, Plescia J, Thronton GB, Languino LR. Structural recognition of a novel fibrinogen gamma chain sequence (117-133) by intercellular adhesion molecule-1 mediates leukocyte-endothelial interaction. J Biol Chem 1995;270:696-699
75. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988;71:831-843
76. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by ADP and epinephrine. J Clin Invest 1979;64:1393-1401
77. Shattil SJ, Kashiwagi H, Pampoti N. Integrin signaling: the platelet function. Blood 1998;91:2645-2657
78. Martinez J, Ferber A, Bach TL, Yaen CH. Interaction of fibrin with VE-cadherin. Ann N Y Acad Sci 2001;936:386-405
79. van Hinsbergh VWM, Collen A, Koolwijk P. Role of fibrin in angiogenesis. Ann N Y Acad Sci 2001;936:426-437
80. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-571
81. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA, del Zoppo GJ. Integrin alpha v beta 3 is expressed in selected microvessels after focal cerebral ischemia. Am J Pathol 1996;149:37-44
82. Clark RAF, Tonnesen MG, Gailit J, Cheresh DA. Transient functional expression of alpha v beta 3 on vascular cells during wound repair. Am J Pathol 1996;148:1407-1421
83. Brooks PC, Montgomery AM, Rosenfeld M, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-1164
84. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500-1502
85. Brooks PC, Stromblad S, Klemke R, Visscher D, Satkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-1822
86. Reynolds LE, Wyder L, Lively JC, et al. Enhanced pathological angiogenesis in mice lacking beta 3 integtin or beta 3 and beta 5 integrin. Nat Med 2002;8:27-34
87. Bader BL, Raybum H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 1998;95:507-519
88. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 1999;103:229-238
89. Carmeliet P. Integrin indecision. Nat Med 2002;8:14-16
90. Cheresh DA, Stupack DG. Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med 2002;8:193-194
91. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-921
92. Dallabrida SM, De Sousa MA, Farrell DH. Expression of antisense to integrin subunit beta 3 inhibits microvascular endothelial cell capillary tube formation in fibrin. J Biol Chem 2000;275:32281-32288
93. Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, Martin GR. Isolation and characterization of type IV procollagen, laminin and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982;21:6188-6193
94. Bayless KJ, Salazar R, Davis GE. RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 2000;156:1673-1683
95. Feng X, Clark RAF, Galanakis D, Tonnesen MG. Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: stabilization of alphav/beta3 mRNA by fibrin1. J Invest Dermatol 1999;113:913-919
96. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659
97. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987;57:673-686
98. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039
99. Bach TL, Barsigian C, Yaen CH, Martinez J. Endothelial cell VE-cadherin functions as a receptor for the beta15-42 sequence of fibrin. J Biol Chem 1998;273:30719-30728
100. Gorlatov S, Medved L. Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor binding site in the NH2-terminal portion of the fibrin beta chains. Biochemistry 2002;41:4107-4116
101. Sahni A, Baker CA, Sporn LA, Francis CW. Fibrinogen and fibrin protect fibroblast growth factor-2 from proteolytic degradation. Thromb Haemost 2000;83:736-741
102. Sahni A, Francis CW. Vascular endothelial growth factor binds to fibrinogen and fibrin and stimulates endothelial cell proliferation. Blood 2000;96:3772-3778
103. Sahni A, Sporn LA, Francis CW. Potentiation of endothelial cell proliferation byfibrin(ogen)-bound fibroblast growth factor-2. J Biol Chem 1999;274:14936-14941
104. Lalla RV, Goralnick SJ, Tanzer ML, Kreutzer DL. Fibrin induces IL-8 expression from human oral squamous cell carcinoma cells. Oral Oncol 2001;37:234-242
105. Collen A, Maas A, Kooistra T, et al. Aberrant fibrin formation and cross-linking of fibrinogen Nieuwegein, a variant with a shortened Aalpha-chain, alters endothelial capillary tube formation. Blood 2001;97:973-980
106. Thompson WD, Smith EB, Stirk CM, Marshall FI, Stout AJ, Kocchar A. Angiogenic activity of fibrin degradation products is located in fibrin fragment E. J Pathol 1992;168:47-53
107. Schlager SI, Dray S. Complete local tumor regression with antibody to fibrin fragment E. J Immunol 1975;115:976-981
108. Taguchi O, Gabazza EC, Yasui H, Kobayashi T, Yoshida M, Kobayashi H. Prognostic significance of plasma D-dimer levels in lung cancer. Thorax 1997;52:563-565
109. Oya M, Akiyamaz Y, Yanagida T, Akoa S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today 1998;28:373-378
110. Blackwell K, Haroon Z, Broadwater G, et al. Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. J Clin Oncol 2000;18:600-608
111. Dirix LY, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. Br J Cancer 2002;86:389-395
112. Myers TJ, Rickles FR, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood 1981;57:518-525
113. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. J Lab Clin Med 1981;98:917-928
114. Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Cancer 1983;51:301-307
115. Edwards RL, Rickles FR, Moritz TE, et al. Abnormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602
116. Edwards RL, Klaus M, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med 1990;89:25-28
117. Yoda Y, Abe T. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease. Thromb Haemost 1981;46:706-709
118. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev 1983;2:41-73
119. Bardos H, Molnar P, Csecsei G, Adany R. Fibrin deposition in primary and metastatic human brain tumours. Blood Coagul Fibrinolysis 1996;7:536-548
120. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer 1991;67:1377-1383
121. Costantini V, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM. Fibrinogen deposition without thrombin generation in primary human breast cancer tissue. Cancer Res 1991;51:349-353
122. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Indirect activation of blood coagulation in colon cancer. Thromb Haemost 1989;62:1062-1066
123. Costantini V, Zacharski LR, Memoli VA, et al. Fibrinogen deposition and macrophage-associated fibrin formation in malignant and non-malignant lymphoid tissue. J Lab Clin Med 1992;119:124-131
124. Wojtukiewicz MZ, Zacharski LR, Memoli VA, et al. Absence of components of coagulation and fibrinolysis pathways in situ in mesothelioma. Thromb Res 1989;55:279-284
125. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. The role of fibrinogen as an extracellular matrix protein. Ann N Y Acad Sci 2001;936:406-425
126. Lee SY, Lee KP, Lim JW. Identification and biosynthesis of fibrinogen in human uterine cervix carcinoma cells. Thromb Haemost 1996;75:466-470
127. Simpson-Haidaris PJ, Courtney MA, Wright TW, Goss R, Harmsen A, Gigliotti F. Induction of fibrinogen expression in the lung epithelium during Pneumocystis carinii pneumonia. Infect Immun 1998;66:4431-4439
128. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-3309
129. Palumbo JS, Degen JL. Fibrinogen and tumor cell metastasis. Haemostasis 2001;31:11-15
130. Contrino J, Goralnick S, Qi J, Hair G, Rickles FR, Kreutzer DL. Fibrin induction of tissue factor expression in human vascular endothelial cells. Circulation 1997;96:605-613
131. Zhang Y, Deng Y, Werndt T, et al. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis-induced tissue factor expression and fibrin deposition in mouse meth A sarcomas. J Clin Invest 1996;97:2213-2224
132. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997;275:547-555
133. Hu Z, Sun Y, Garen A. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. Proc Natl Acad Sci USA 1999;96:8161-8166
134. Hu Z, Garen A. Targeting tissue factor on tumor vasculature endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. Proc Natl Acad Sci USA 2001;98:12180-12185
135. Nilsson F, Kosmehl H, Zardi L, Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001;61:711-716
136. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-1615
137. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine and SU5416 in patients with solid tumors. J Clin Oncol 2002;20:1657-1667
138. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol 2002;20:1446-1448
139. Osman K, Comenzo R, Rajkumar SV. Deep vein thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001;344:1951-1952
140. Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002;100:1168-1171
141. Urbauer E, Kaufmann H, Nosslinger T, Raderer M, Drach J. Thrombotic events during treatment with thalidomide. Blood 2002;99:4247-4248
142. Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A. Thalidomide and venous thrombosis. Ann Intern Med 2002;136:711
143. Kaushal V, Kohli M, Zangari M, Fink L, Mehta P. Endothelial dysfunction in antiangiogenesis-associated thrombosis. J Clin Oncol 2002;20:3042
144. Cavo M, Zamagni E, Cellini C, et al. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood 2002;100:2272-2273
145. Cosgrove RH, Zacharski LR, Racine E, Andersen JC. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost 2002;28:79-87
146. Prandoni P, Lensing AW, Büller HR, et al. Comparison of subcutaneous low-molecular-weight heparins with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992;339:441-445
147. Hettiarachchi RJK, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Büller HR. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost 1999;82:947-952
148. Smorenburg SM. Inhibition of angiogenesis with heparin? Haemostasis 2001;31(suppl 1):25-29
149. Norrby K, Østergaard P. Basic-fibroblast-growth-factor-mediated de novo angiogenesis is more effectively suppressed by low-molecular-weight than by high-molecular-weight heparin. Int J Microcirc Clin Exp 1996;16:8-15
150. Moussa SA. Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 2002;28:45-52
151. Collen A, Smorenburg SM, Peters E, et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000;60:6196-6200
152. Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin Thromb Hemost 2002;28:53-66
153. Lever R, Page CP. Novel drug development opportunities for heparin. Nat Rev Drug Discov 2002;1:140-148
154. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood 2002;100:3790-3796